Current Value
$0.851 Year Return
Current Value
$0.851 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PLOW | 50.02% | $563.49M | +5.90% | 4.80% |
CVLT | 41.64% | $7.00B | +62.57% | 0.00% |
HSII | 41.59% | $872.52M | +33.84% | 1.42% |
VRNS | 39.91% | $4.50B | -18.20% | 0.00% |
FFIV | 39.42% | $15.13B | +39.68% | 0.00% |
SEG | 37.01% | $262.44M | -19.74% | 0.00% |
BRX | 36.07% | $7.79B | +14.94% | 4.31% |
HLIT | 34.98% | $1.22B | -17.13% | 0.00% |
LGIH | 34.45% | $1.68B | -32.83% | 0.00% |
CNO | 34.28% | $4.04B | +51.19% | 1.59% |
RNGR | 33.80% | $317.33M | +23.14% | 1.82% |
TENB | 33.74% | $4.34B | -21.52% | 0.00% |
FISI | 31.90% | $507.31M | +40.73% | 5.77% |
HWM | 31.07% | $51.24B | +90.99% | 0.25% |
SWK | 30.95% | $12.50B | -8.15% | 4.04% |
KRG | 30.43% | $4.78B | +4.72% | 4.76% |
HAYW | 28.99% | $3.06B | -0.77% | 0.00% |
BFS | 28.84% | $874.37M | -1.87% | 6.52% |
SFM | 28.40% | $13.48B | +111.92% | 0.00% |
NEO | 28.31% | $1.26B | -33.12% | 0.00% |
SeekingAlpha
Imunon, Inc. (NASDAQ:IMNN) Q4 2024 Results Conference Call February 26, 2025 11:00 AM ETCompany ParticipantsPeter Vozzo - ICR Healthcare, IRStacy Lindborg -...
Yahoo
By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Gearing Up to Initiate Phase 3 Ovarian Cancer Trial Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial of its lead development compound, IMNN-001, in patients with advanced ovarian cancer. IMNN-001 is a DNA immunotherapeutic drug that consists of an interleukin (IL)-12
Yahoo
Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components assures a high-quality, commercially viable future manufacturing capability On track to initiate Phase 3 pivotal trial of IMNN-001 in first quarter of 2025 LAWRENCEVILLE, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the p
Yahoo
Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT) population of women newly diagnosed with advanced ovarian cancer Median OS increased from 11 to 13 months in IMNN-001 treatment group based on latest data analysis No change in IMNN-001 favorable safety profile including no reports of serious immune-related adverse events IMUNON remains on track to initiate Phase 3 pivotal trial of IMNN-001 in Q1 2025 LAWRENCE
Yahoo
By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Reaches Alignment with FDA Regarding Phase 3 Trial Plan On November 25, 2024, Imunon, Inc. (NASDAQ:IMNN) announced it had reached alignment with the U.S. Food and Drug Administration (FDA) following an ‘End-of-Phase 2’ meeting on the company’s proposed plan for a Phase 3 trial of IMNN-001 in patients with advanced
Yahoo
FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment schedule, and primary endpoint Final Protocol submission on track for December, supporting initiation of Phase 3 registrational trial in Q1 2025 LAWRENCEVILLE, N.J., Nov. 25, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the outcome of its recent
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
JMBS | -<0.01% | $5.08B | 0.23% |
SHV | -<0.01% | $19.68B | 0.15% |
DGS | 0.01% | $1.59B | 0.58% |
CWI | 0.02% | $1.68B | 0.3% |
IYK | -0.03% | $1.49B | 0.4% |
SPTM | 0.04% | $9.17B | 0.03% |
PGJ | -0.05% | $161.17M | 0.67% |
COM | 0.05% | $245.08M | 0.72% |
OVT | -0.05% | $62.95M | 0.8% |
AOK | 0.06% | $592.72M | 0.15% |
SECT | 0.06% | $1.83B | 0.78% |
VRP | 0.06% | $2.03B | 0.5% |
CARY | -0.08% | $347.36M | 0.8% |
SCHJ | -0.09% | $510.22M | 0.03% |
DXJ | 0.09% | $3.44B | 0.48% |
IVAL | -0.09% | $130.81M | 0.39% |
BKCH | -0.10% | $121.94M | 0.5% |
VTI | -0.10% | $433.98B | 0.03% |
FLJH | -0.10% | $85.74M | 0.09% |
GIGB | -0.11% | $841.94M | 0.08% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BILZ | 40.18% | $734.34M | 0.14% |
RSPH | 15.10% | $792.25M | 0.4% |
KIE | 14.58% | $913.48M | 0.35% |
PBDC | 14.04% | $182.90M | 13.94% |
XMLV | 13.91% | $758.61M | 0.25% |
FDL | 13.79% | $5.14B | 0.45% |
BIZD | 13.58% | $1.46B | 13.33% |
PWV | 13.50% | $994.60M | 0.53% |
FTA | 13.28% | $1.10B | 0.6% |
HDV | 13.11% | $10.90B | 0.08% |
JAAA | 13.01% | $22.07B | 0.21% |
SCHD | 12.95% | $68.07B | 0.06% |
IAK | 12.74% | $755.80M | 0.39% |
RPV | 12.55% | $1.28B | 0.35% |
DRLL | 12.52% | $286.52M | 0.41% |
FXG | 12.38% | $280.33M | 0.63% |
SMMV | 12.26% | $278.59M | 0.2% |
PEY | 12.20% | $1.17B | 0.53% |
RSPF | 12.12% | $295.92M | 0.4% |
XSLV | 12.09% | $274.37M | 0.25% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
JUCY | -17.75% | $301.88M | 0.6% |
CPNJ | -14.55% | $30.69M | 0.69% |
YLD | -12.42% | $297.25M | 0.39% |
TBLL | -11.87% | $2.04B | 0.08% |
IBTF | -11.21% | $2.22B | 0.07% |
SMH | -10.88% | $19.91B | 0.35% |
PSI | -10.74% | $616.07M | 0.56% |
FTXL | -10.69% | $247.58M | 0.6% |
CLOA | -10.47% | $780.86M | 0.2% |
SOXQ | -9.65% | $400.21M | 0.19% |
XLK | -9.64% | $64.48B | 0.09% |
QQA | -9.57% | $161.30M | 0% |
SOYB | -9.16% | $25.48M | 0.22% |
IXN | -8.77% | $4.49B | 0.41% |
CGCP | -8.73% | $4.58B | 0.34% |
SOXX | -8.57% | $11.28B | 0.35% |
CPSJ | -8.48% | $33.88M | 0.69% |
FFOG | -8.39% | $110.64M | 0.55% |
SPMO | -8.32% | $5.10B | 0.13% |
TPMN | -8.20% | $33.23M | 0.65% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PTMN | <0.01% | - | - | 17.41% |
BP | <0.01% | $88.41B | -10.94% | 5.60% |
FMC | 0.01% | $5.21B | -35.91% | 5.51% |
BRZE | -0.01% | $3.65B | -29.99% | 0.00% |
GEL | 0.02% | $1.62B | +26.31% | 4.63% |
HDB | -0.02% | $154.76B | +9.87% | 1.14% |
ADUS | 0.02% | $1.64B | -6.70% | 0.00% |
PAY | 0.03% | $3.48B | +28.07% | 0.00% |
AER | 0.03% | $18.93B | +18.06% | 1.01% |
ARVN | 0.04% | $579.75M | -81.20% | 0.00% |
QNRX | 0.04% | $1.54M | -68.20% | 0.00% |
CVAC | 0.04% | $675.16M | -8.79% | 0.00% |
GOLF | 0.05% | $3.91B | +5.27% | 1.35% |
SPRU | 0.05% | $47.81M | -33.59% | 0.00% |
RDY | 0.05% | $10.56B | -15.74% | 3.76% |
TPC | -0.06% | $1.34B | +100.00% | 0.00% |
PCT | 0.06% | $1.38B | +44.19% | 0.00% |
PFLT | -0.07% | - | - | 12.07% |
WBX | 0.07% | $89.89M | -76.07% | 0.00% |
SFIX | -0.07% | $462.61M | +70.22% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
WWD | -49.70% | $10.72B | +21.86% | 0.57% |
QXO | -44.00% | $5.25B | -86.07% | 0.00% |
AMKR | -34.81% | $4.84B | -36.29% | 1.68% |
ECL | -34.51% | $71.02B | +10.70% | 0.95% |
MRK | -28.36% | $238.89B | -22.18% | 3.31% |
LTC | -27.24% | $1.63B | +11.71% | 6.37% |
MBIN | -26.74% | $1.74B | -4.56% | 1.22% |
PG | -23.19% | $393.86B | +4.08% | 2.39% |
TLK | -21.53% | $14.82B | -40.80% | 7.27% |
SYM | -20.67% | $2.33B | -52.27% | 0.00% |
LITB | -17.39% | $19.12M | -77.83% | 0.00% |
BMO | -17.31% | $70.61B | +3.24% | 4.57% |
XYL | -17.19% | $29.84B | -3.54% | 1.21% |
RMBS | -17.06% | $5.82B | -10.11% | 0.00% |
BHE | -17.04% | $1.42B | +32.19% | 1.68% |
PSN | -17.02% | $6.22B | -28.63% | 0.00% |
GLW | -16.94% | $40.04B | +43.80% | 2.40% |
CAMT | -16.61% | $2.99B | -13.46% | 0.00% |
TRS | -16.47% | $980.08M | -3.09% | 0.66% |
NVDA | -16.15% | $2.97T | +38.52% | 0.03% |